Main Article Content
OBJECTIVES: To propose the benefit of antifibrotic agent, nintedanib, in the treatment of lung fibrosis from SARS-CoV-2 Coronavirus 2019 (COVID-19) pneumonia, based on experience at Bangkok Hospital Headquarters, Bangkok, Thailand.
MATERIALS AND METHODS: Data from patients who developed lung fibrosis post COVID-19 pneumonia during 2020-2022 at our institute, all developed severe pneumonia, was analyzed, including clinical signs and symptoms, imaging findings, O2 saturation: at room air and during 6 minutes’ walk, and response to treatment.
RESULTS: Among 10 patients with COVID-19 lung fibrosis who received steroids, remdesivir and nintedanib; 2 patients (20%) expired, 7 patients (70%) were back to normal within 3 months, and 1 patient (10%) was able to walk with oxygen 2 liter per minute (LPM) after 7 months.
CONCLUSION: An antifibrotic agent, such as nintedanib, could improve lung fibrosis from COVID-19 pneumonia.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mamun SMAA, Jahan R, Islam QT, et al. Rational of using common antifibrotic therapy in post COVID fibrosis. J Med 2021;22(1):46-50. ID: covidwho-1059839
Chung MP, Park MS, Oh IJ, et al. Safety and efficacy of perfenidine in advanced idiopathic pulmonary fibrosis. Adv Ther 2020;37(5);2303-16. doi: 10.1007/s12325-020-01328-8.
Thille AW, Estaban A, Fernandez-Segoviano P, et al. Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: A prospective cohort study of clinical autopsies. Lancet Respir Med 2013;1(5):395-401. doi: 10.1016/S2213-2600(13)70053-5.
Umemaru Y, Mitsuyama Y, Minami K, et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study. Int J Infect Dis 2021;108:454-60. doi: 10.1016/j.ijid.2021.05.055.
Ogata H, Nakagawa T, Sakoda S, et al. Nintedanib treatment for pulmonary fibrosis aftercoronavirus 2019. Respirol Case Rep 2021;9(5):e00744. doi: 10.1002/rcr2.744.
Vitug LC, Santiaguel J. Nintedanib as in adjunct treatment in improving lung function of post-COVID-19 pulmonary fibrosis in an elderly patient: a case report. Chest 2021:160(4):A2166. doi: 10.1016/j.chest.2021.07.1914
Singh P, Behera D, Gupta S, et al. Nintedanib vs perfenidone in the management of COVID-19 lung fibrosis: A single center study. JRCPE 2022:1-6. doi: 10.1177/14782715221103402